CONCORD, Calif.-- (BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood ...

Concord, Calif.-based Cerus announced today an agreement with the Biomedical Advanced Research and Development Authority, a segment of the U.S. Department of Heath and Human Services’ Office of the ...

Cerus Corporation (NASDAQ:CERS) saw its stock climb 3.3% following news of a $7.2 million contract amendment from the U.S. Department of Defense (DoD). The new funding expands the company’s existing ...

Samsung Electronics forecasted strong artificial intelligence-driven demand for chips in the second half of this year, as it reported a more than 15-fold rise in its second-quarter operating profit.

Regulatory Approval Allows Company to Initiate Commercialization of the Illumination Device throughout the European Union CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (CERS) announced today ...